Content Type: Article

  • Key Considerations for Investments in Entities Developing Innovative FDA-Regulated Products

    Key Considerations for Investments in Entities Developing Innovative FDA-Regulated Products

    ARTICLE

    Key Considerations for Investments in Entities Developing Innovative FDA-Regulated Products

    December 2. 2019

    Read time: 2 min

    Key takeaways
    Overview

    Digital health and other life sciences/tech developers, particularly those producing innovative new solutions, offer dynamic opportunities for investors, in part due to the continued evolution of the US Food and Drug Administration’s (FDA’s) approach to regulatory oversight. In this article, the sixth in our Focus on Innovation Centers series, Vernessa Pollard and Michael Ryan outline four important factors that hospital and health system (HHS) innovation executives should consider when investing in companies that are developing FDA-regulated products.

    In depth
    Authors

    Michael W. Ryan

    Partner

    Washington, DC

    More insights

  • Brexit—What Now?

    ARTICLE

    Brexit—What Now?

    November 27, 2019

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • IP Update Vol. 22, No. 11

    IP Update Vol. 22, No. 11

    ARTICLE

    IP Update Vol. 22, No. 11

    November 2019

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Paul Devinsky

    Senior Counsel

    Washington, DC

    Amol Parikh

    Partner

    Chicago

    More insights

  • Proposed HSR Act Rules to Increase Reporting for Funds Making Minority Investments in Foreign Issuers

    Proposed HSR Act Rules to Increase Reporting for Funds Making Minority Investments in Foreign Issuers

    ARTICLE / CLIENT ALERT

    Proposed HSR Act Rules to Increase Reporting for Funds Making Minority Investments in Foreign Issuers

    November 25, 2019

    Read time: 13 min

    Key takeaways
    Overview

    The Federal Trade Commission (“FTC”) recently published, with the concurrence of the Department of Justice Antitrust Division (“DOJ”), proposed regulations that would considerably narrow the availability of the HSR Act “foreign to foreign” minority shareholding exemption provided by 16 CFR § 802.51(b)(1).

    The proposed regulations primarily affect U.S.-managed/foreign-domiciled investment funds and foreign-managed/foreign-domiciled funds making minority investments in foreign issuers.[1] The proposed rules will instantly transform the HSR status of every Cayman (or other foreign domiciled) limited partnership fund with a U.S. manager to the United States, denying them the ability to use the § 802.51(b) exemption.[2] And for foreign-managed/foreign-domiciled funds, many of the foreign entities in which they invest will no longer be considered foreign for HSR purposes, denying the § 802.51(b) exemption for their holdings in these issuers.

    The new rules also may make it more difficult, and in some cases impossible, for a prospective minority investor to ascertain whether the company in which it wishes to invest is eligible for the “foreign to foreign” exemption. The proposed rules accomplish these results by changing the longstanding test for what constitutes an entity’s “principal offices.”[3]

    This Alert describes the current rule, the proposed new rules, and the impact that the proposed new rules would have on funds that may acquire minority holdings in foreign issuers.

    The Current Rule

    The Hart Scott Rodino Antitrust Improvements Act (“HSR”) requires that certain transactions, including the acquisition of voting securities valued in excess of $90 million, be notified to the FTC and DOJ prior to consummation, unless otherwise exempt.[4] The purpose of HSR notification is to permit the antitrust agencies to evaluate transactions in advance to determine whether they raise competitive concerns. Under 16 CFR § 802.51(b)(1), the acquisition by a foreign person of the voting securities of a foreign issuer is exempt from HSR reporting, so long as the foreign acquiring person will not obtain control (50% or more) of the foreign issuer. This is commonly referred to as the “foreign to foreign exemption.” The FTC stated in promulgating this rule that the exemption “recognizes that considerations of comity may be significant in the area of international business transactions. With respect to some acquisitions whose principal impact is foreign, it is appropriate for the agency, in its discretion, to exercise a self-imposed limitation and decline to subject them to the [HSR] act’s requirements…an anticompetitive impact upon United States commerce is less likely to occur when a foreign person is acquiring foreign…voting securities.”[5]

    Under the current definition of “foreign person,” foreign status is determined by meeting three objective criteria: (1) the entity must be incorporated in a foreign country; (2) the entity must be organized under the laws of a foreign country; and (3) the entity must have its “principal offices,” which the FTC describes as the “single location which the person regards as the headquarters office of the ultimate parent entity,”[6] outside of the United States.

    In the vast majority of cases, the headquarters location for a publicly listed or large private company can be easily found in SEC or foreign securities law filings, the company’s annual report or its website. If there are multiple headquarters, or the headquarters location is unclear, the FTC Premerger Notification Office (“PNO”) has issued informal interpretations to guide parties in evaluating additional factors to determine a company’s principal office.

    The PNO has also advised as to determining principal offices for investment funds organized as a partnership under the laws of a foreign country and that have no principal offices. For such entities, the PNO treats the fund as foreign even if the fund’s general partner or management company (a third party not within the same “person” of the fund) has its principal offices in the United States.[7]

    Thus, the current rules exempt both U.S.-managed and foreign-managed, foreign-domiciled funds (e.g., Cayman Islands limited partnerships), in acquisitions of minority positions in a foreign issuer’s voting securities. For such funds that invest only in non-controlling positions, the current rules mean that they do not need to worry about HSR compliance for the acquisition of any foreign issuer because of the § 802.51(b)(1) exemption.[8] This broad exemption simplifies the fund’s compliance obligations.

    The Proposed Rule

    Under § 802.51(b)(1), the acquisition by a foreign person of the voting securities of a foreign issuer will remain exempt, so long as the foreign acquiring person will not obtain control (50% or more) of the foreign issuer. This rule will not be changed. However, its application may be narrowed considerably by the redefinition of what constitutes a foreign entity or foreign issuer, turning many entities that are now considered foreign under the HSR rules into U.S. entities and making issuers no longer entitled to benefit from the § 802.51(b)(1) exemption.

    Under the proposed definitions of foreign person,[9] foreign status is determined by meeting the same three criteria: (1) the entity must be incorporated in a foreign country; (2) the entity must be organized under the law of a foreign country; and (3) the entity must have its “principle offices” outside of the United States, which the proposed regulations change from a simple test as to the location that the entity regards as its headquarters to the location at which more than 50%[10] of:

    1. The ultimate parent entity’s officers reside; or
    2. The ultimate parent entity’s directors reside (in the case of an entity lacking officers and directors, the analysis is based on individuals exercising similar functions); or
    3. The ultimate parent entity’s assets are located (including the assets of all entities that the ultimate parent entity controls directly or indirectly), based on fair market value.[11]

    The FTC states that “officers” will be defined as:

    Individuals in positions that are either (1) provided for in the entity’s articles of incorporation or by-laws, or (2) appointed by the board of directors. [T]he proposed rule looks to the officers and directors of the entity’s ultimate parent [or the issuer].[12]

    The FTC also says that for entities that do not have officers or directors:

    If, for example, a limited partnership is not organized under U.S. law and does not have officers and directors, it must look to individuals exercising similar functions for the partnership. Serving as the equivalent of an officer or director includes making decisions regarding, and overseeing, the day-to-day affairs of the partnership. For example, those “exercising similar functions” for an investment fund partnership may include the general partner of the partnership, and/or any investment manager.[13]

    The FTC appears uncertain as to how it will assess the residency of officers and directors:

    The Commission invites comments on whether clarification is needed on the question of how an individual’s residency is to be determined and, if so, what factors should be used in that determination. Factors could include:

    1. The location of an individual’s primary residence;
    2. The individual’s primary tax residence;
    3. The country where he or she resides for at least half of the calendar year; or
    4. The location of at least half of the total real property owned by the individual.[14]

    Under the proposed rules, the asset evaluation analysis is not guided by accounting or book value, rather:

    In determining whether 50% or more of the UPE’s or issuer’s assets are located in the U.S., the proposed amendments rely on the fair market value of the relevant entity’s assets, determined in accordance with § 801.10(c)(3) of the Rules. This includes both tangible and intangible assets.[15]

    In sum, the proposed regulations (1) repeal the current PNO guidance and re-designate U.S.-managed foreign-domiciled LP funds as U.S. persons; and (2) require a foreign investor making a minority acquisition of a foreign issuer’s voting securities to obtain and evaluate a new list of information about the foreign issuer, its officers and directors in order to determine whether the § 802.51(b) exemption applies.

    Comments and Observations

    1. The proposed rules will expand the HSR reporting obligations for certain foreign-domiciled funds making minority acquisitions of foreign voting securities.

    The managed fund industry had initially hoped that under the current administration, the FTC would take a more measured approach toward requiring HSR notification for minority voting securities holdings by funds, a category of transactions unlikely to raise antitrust concerns. This hope stemmed from the two Republican Party appointed FTC commissioner dissents in the 2015 Third Point HSR Act enforcement action.[16] In dissenting, these commissioners “strongly encourage[d] …potential modification to the HSR Rules…to eliminate filing requirements for a category of [minority interest] stock acquisitions that have proven unlikely after 40 years of experience to raise competitive concerns.”[17] [18] Thus, the proposed FTC regulations that increase HSR filing requirements for minority investments by funds may seem somewhat surprising to some observers.

    1. The rules propose a potentially problematic test for determining a foreign issuer’s status.
    2. The information required for the test may be indeterminable by a potential investor.

    Setting aside the policy merits of extending HSR reporting obligations to funds making minority investments in foreign issuers, it is potentially problematic that a rule that applies to minority investments in foreign legal entities requires the potential minority investor to obtain and evaluate a significant amount of non-public information about the foreign legal entity, its officers and directors. It is not common for a potential minority investor to be afforded the extensive due diligence potentially required to determine the issuer’s “principle offices” under the proposed rules.

    Indeed, it may at times be impossible for a potential minority investor to be able to obtain such information. There is no legal or fiduciary obligation for any issuer, U.S. or foreign, to supply the information the proposed rules necessitate be evaluated. Indeed, under restrictive EU privacy rules, an EU-based foreign issuer may be unable, as a matter of law, to provide to a potential third-party investor the detailed personal and financial information on its officers and directors required by the proposed rule. See attached Exhibit A for a comparison of the information and analysis required by the current test and for the proposed test.

    1. The information required for the test is subject to frequent change.

    Further, even if it were easy for a third-party minority investor to obtain sufficient information to undertake the multi-factor assessment required by the proposed rules, the criteria the FTC prescribes for determining the principle offices will be a moving target. The current criteria for determining a company’s headquarters is simple and not subject to frequent change. Moving a physical headquarters office or legally re-domiciling a company are rare events.

    Under the new rules, for a foreign entity, the mere election of a new director with a different residence from the predecessor, the acquisition by a company vice president of a new vacation home, or the acceptance of a visiting faculty position with a U.S. business school, could each potentially tip the 50% balance of the officer/director residency ratio — instantly transforming an exempt foreign issuer into a non-exempt U.S. issuer. Similarly, if a foreign issuer sells a large foreign subsidiary or pays a significant dividend to shareholders from funds accumulated in a foreign bank account, its relative over/under 50% fair market value asset allocation between the United States and the rest of the world could flip, converting the issuer’s status from foreign to U.S. Thus, for some foreign entities close to the 50% line on any of the criteria, a potential minority investor may need to undertake the proposed extensive analysis each and every time it buys a share of stock.[19]

    Conclusion

    The proposed regulations will have the likely effect of increasing the number of HSR filings by investment funds (both U.S. and foreign managed) making minority investments in the voting securities of foreign issuers. The proposed rules extend HSR reporting obligations to a category of acquisitions that the original regulations noted are unlikely to have an anticompetitive impact within the United States, and that in the over 40 years since have proven unlikely to raise competitive concerns. In many cases, foreign investor minority acquisitions of foreign issuers that are not reportable to competition authorities in their home countries will now be reportable to the United States antitrust agencies.

    Further, the proposed rules require a potential minority investor to assess confidential non-public information about the foreign issuer that may not be available to it in order to determine whether the “foreign to foreign” exemption applies. Parties unable to determine whether the exemption applies will either have to guess, at the risk of a civil penalty that exceeds $1.2 million per month if they are wrong, or to be safe, file a perhaps unnecessary HSR notification, pay the $45,000 to $280,000 HSR filing fee, and wait the full 30-day review period prior to making a minority investment in a foreign issuer.

    The FTC is accepting comments on the proposed regulations through Dec. 30, 2019. If you would like further information or assistance in commenting on the proposed rules, please contact the authors.

    To view Exhibit — A Comparison of the Current and Proposed Rules.

    Authored by Peter Jonathon Halasz and Gregory L. Kinzelman.


    [1] Transactions that give a U.S. or foreign person control (50% or greater ownership) over a foreign person or issuer will continue to be potentially subject to HSR notification, as at present.

    [2] However, a U.S.-managed Cayman fund organized as a “Limited” company (regardless as to whether it elects to be taxed as a partnership) could still be considered foreign if it has a majority of non-U.S. officers and directors. See PNO Informal Interpretation 1412010, Dec. 30, 2014, annotated April 1, 2015, available here.

    [3] 84 Fed. Reg. 58348 (Oct. 31, 2019).

    [4] While there is an HSR exemption for parties that acquire less than 10% of an issuer’s voting securities “solely for purposes of investment” (16 CFR § 802.9), that exemption does not apply to activist funds, funds with a board seat, and funds meeting other criteria. Further, the FTC has aggressively challenged parties’ reliance on this exemption. Given the chilling effect of the $42,530 per day civil penalty for failing to file under HSR, parties may be reluctant to rely on the § 802.9 exemption if there is a risk that the FTC disagrees with its application to a particular transaction.

    [5] 43 Fed. Reg. 33497, 33498 (July 31, 1978).

    [6] See 43 Fed Reg. 33461.

    [7] See ABA Premerger Notification Practice Manual, 5th Edition (2015), at 275-6.

    [8] Because the § 802.51(b) exemption applies to any position under 50%, the intent of the investor is not relevant.

    [9] To be codified as a new 16 CFR § 801.1(e )(1)(i) and (ii), and (2)(i) and (ii).

    [10] A 50% — 50% tie, or greater than 50% of any of these criteria being U.S. renders the entity or issuer.

    [11] 84 Fed. Reg. 58352.

    [12] 84 Fed. Reg. 58350.

    [13] Ibid.

    [14] Ibid.

    [15] Ibid. (emphasis supplied).

    [16] Dissenting Statement of Commissioners Maureen K. Ohlhausen and Joshua D. Wright, In the Matter of Third Point, April 24, 2015, available here.

    [17] Id. at 4.

    [18] We can find no record of an investment fund’s minority investment that has been challenged as a violation of substantive antitrust law. In FY2018 and FY2017, for HSR filings where the acquiring person reported the NAICS code for “funds, trusts and other financial vehicles,” out of 160 reported transactions, none resulted in either agency seeking clearance to investigate, no second requests were issued, and no transactions were challenged. See HSR Annual Reports available here. Indeed, over the past decade, there have only been two second request investigations out of 434 transactions where the acquiring person filed under the investment fund NAICS code.

    [19] If a foreign investor relies on the foreign to foreign exemption and previously acquired $90 million of the voting securities of an issuer newly meeting the new “foreign” criteria without filing under the HSR Act, the change of the status of the foreign issuer to U.S. would mean that the purchase of a single additional share would potentially trigger the need for HSR reporting.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2019 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Peter Jonathan Halasz

    Of Counsel

    New York – 919 Third Avenue

    More insights

  • SEC’s Disgorgement Authority Under Review

    SEC’s Disgorgement Authority Under Review

    ARTICLE / CLIENT ALERT

    SEC’s Disgorgement Authority Under Review

    November 22, 2019

    Read time: 8 min

    Key takeaways
    Overview

    On Nov. 19, 2019, the U.S. House of Representatives passed the Securities Fraud Enforcement and Investor Compensation Act with wide bipartisan support in a 314-95 vote.[1] The bipartisan support of the House bill indicates strong interest in expanding the enforcement authority and remedies currently available to the SEC in federal court. It comes on the heels of a 2017 decision by the U.S. Supreme Court, which limited some remedies available to the SEC, and another case, just accepted for review, that may further limit the remedies the SEC can seek in federal court.

    The House bill and the cases before the Supreme Court deal with the SEC’s authority to seek a remedy known as disgorgement. Disgorgement refers to the SEC’s ability to require those who violate the securities laws to forfeit any ill-gotten gains. For a long time, the SEC operated under the assumption that it had the authority to seek disgorgement as a remedy in federal court under its broad mandate to pursue “equitable relief.” This assumption has been challenged in federal courts in recent years as it is not expressly granted by statute. The availability of this remedy as an enforcement tool is far from trivial. According to the Division of Enforcement’s latest report, the agency had a record year in FY2019, with over $3.2 billion in disgorgement ordered against individuals and entities sued by the SEC.[2]

    While the status of the House bill in the U.S. Senate is unclear, a companion to it has bipartisan sponsors in Senators Mark Warner (D-VA) and John Kennedy (R-LA).[3] The Senate bill would expressly grant the SEC authority to pursue restitution for up to 10 years, and to pursue disgorgement for up to five years. While disgorgement limits the SEC to recovering unlawful profits, restitution would provide the agency authority to recover the full amount of investor losses. The Senate bill is currently pending action in the Senate Banking Committee.

    If Congress passes legislation along these lines, the future effects of the case currently before the Supreme Court would be limited. Either way, it appears likely that either Congress or the courts (or both) will provide clarity in the coming months about the enforcement tools the SEC has at its disposal.

    The Case Currently Before the U.S. Supreme Court

    The passage of the House bill came after the Supreme Court’s decision earlier this month to hear an appeal in SEC v. Liu. In Liu, the court is reviewing the same question the House addressed in its bill: “[w]hether the Securities and Exchange Commission may seek and obtain disgorgement from a court as ‘equitable relief’ for a securities law violation even though this Court has determined that such disgorgement is a penalty.”

    This case follows up on a 2017 Supreme Court decision on a more narrow question in Kokesh v. SEC, which held that disgorgement actions in federal court were subject to a five-year statute of limitations.[4] The broader question in Liu contemplates, and could significantly limit, the recovery available to the SEC in federal court actions.

    Background

    Under 28 U.S.C. § 2462, the SEC’s ability to seek punitive relief against a defendant is restricted by a statute of limitations.[5] Specifically, “enforcement of any civil fine, penalty, or forfeiture, pecuniary or otherwise,” must take place within a five-year period of when the claim arose — known as a statute of limitations.[6] Accordingly, federal courts have grappled with the question of whether certain SEC actions — the ordering of disgorgement among them — constitute “punitive relief,” which is restricted by the statute of limitations, or “equitable relief” which is not subject to that statute of limitations. In Kokesh v. SEC, the Supreme Court puts to rest this question in finding that that SEC disgorgement orders are punitive, and therefore, subject to the five-year statute of limitations, because such orders “go beyond compensation, are intended to punish, and label defendants wrongdoers’ as a consequence of violating public laws.” [7] A prior SRZ Alert[8] discusses in detail the implications of Kokesh.

    In its decision, the Kokesh Court did not directly address whether the SEC had the statutory authority to pursue disgorgement in federal court. Instead, it highlighted this looming issue in a footnote, ominously writing that “nothing in this opinion should be interpreted as an opinion on whether courts possess authority to order disgorgement.”[9] In Liu, the Court has taken on the mantle of deciding this very question.

    In 2018, the SEC obtained a judgment against defendant Liu and others in U.S. District Court for fraudulently raising and misappropriating $27 million from investors in a scheme related to the EB-5 visa program. The court ordered the defendants to disgorge more than $26 million in profits and pay an additional $8 million in other penalties.[10]

    The defendants appealed the ruling to the U.S. Court of Appeals for the Ninth Circuit, arguing that the SEC did not have the statutory authority to seek disgorgement, citing the footnote in Kokesh. In affirming the District Court, the Ninth Circuit pointed out that Kokesh “expressly refused to reach this issue,”[11] and therefore, the court needed to rely on its own precedent, which permitted the SEC to pursue disgorgement. The defendants appealed this ruling to the U.S. Supreme Court, which granted certiorari.

    Recent history suggests that the Supreme Court is sympathetic to the view of Liu and his co-defendant here. Appellants petition to the court notes that during oral arguments in Kokesh, four currently sitting justices observed that the SEC does not have any clear statutory authority for disgorgement (Justices Roberts, Alito, Sotomayor and Gorsuch).[12]  Absent action from Congress, a decision to strip the SEC of its authority to pursue disgorgement in federal court would significantly limit the remedies available in the agency’s enforcement actions.

    The Supreme Court has not yet scheduled oral arguments in the case, which will likely be decided no later than the end of June.

    Implications for Parties to SEC Investigations

    The SEC collects billions of dollars in disgorgement from defendants annually. Disgorgement has become a primary tool used by the SEC to recover for securities law violations and the availability of disgorgement as a remedy gives the agency significant leverage in settlement negotiations. A decision in favor of the petitioners in the Supreme Court would curtail the SEC’s ability to pursue disgorgement in civil actions filed in federal court, which has already been limited to those within the statute of limitations by Kokesh. Yet, if Congress grants express authority to the SEC, this would trump any Supreme Court decision here on a going-forward basis, and would provide expanded enforcement authority to the SEC.

    There appears to be bipartisan support in Congress for expanding the enforcement powers of the SEC regardless of how the Supreme Court decides Liu. Both the House and Senate bills contemplate extending the statute of limitations and, while the details of both bills are subject to change, the clear indication is that Congress envisions more express enforcement authority for the SEC, rather than less. This change would significantly expand the remedies available to the SEC and may increase the number of enforcement actions the SEC brings in federal court.

    Authored by Charles J. Clark, Marc E. Elovitz, Craig S. Warkol and Peter H. White.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the attorneys in the firm’s Securities Enforcement Group or White Collar Defense & Government Investigations Group.


    [1] H.R. 4344, 116th Cong. (2019).

    [2] 2019 Annual Report, Sec. & Exch. Comm’n Div. of Enf’t (2019), available here.

    [3] S. 799, 116th Cong. (2019).

    [4] Kokesh v. SEC, 137 S. Ct. 1635 (2017). The SEC already has express statutory authority to pursue disgorgement in enforcement actions filed before its own Administrative Law Judges.

    [5] 28 U.S.C. § 2462.

    [6] Id.

    [7] Kokesh, 137 S. Ct. at 1643.

    [8] “Supreme Court: SEC Disgorgement Claims Are Subject to Five-Year Statute of Limitations,” SRZ Alert, June 6, 2017, available here.

    [9] Id. at n.3.

    [10] SEC v. Liu, 262 F. Supp. 3d 957 (C.D. Cal. 2017).

    [11] SEC v. Liu, 754 F. App’x 505, 509 (9th Cir. 2018), cert. granted.

    [12] Petition for Writ of Certiorari, Liu v. SEC, No. 18-1501 (U.S. May 31, 2019).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2019 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    More insights

  • RGPD: Communities and Public Service Managers, Who is Responsible for What?

    ARTICLE

    RGPD: Communities and Public Service Managers, Who is Responsible for What?

    November 21, 2019

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • OFAC Expands Reporting Obligations and Highlights Importance of Cooperation

    OFAC Expands Reporting Obligations and Highlights Importance of Cooperation

    ARTICLE / CLIENT ALERT

    OFAC Expands Reporting Obligations and Highlights Importance of Cooperation

    November 21, 2019

    Read time: 8 min

    Key takeaways
    Overview

    In June 2019, the U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”) issued an interim final rule amending the Reporting, Procedures and Penalties Regulations (“RPPR”), 31 CFR Part 501 (“Interim Final Rule”).[1] Most importantly, the Interim Final Rule, which became effective on June 21, 2019, imposes new requirements relating to who must file reports on rejected transactions with OFAC and what transactions must be reported. Most recently, at its Symposium on Nov. 12, 2019, OFAC emphasized the importance of these new requirements.

    Expanding Reporting Requirements

    The Interim Final Rule significantly broadens the reporting requirements under 31 CFR § 501.604 by expanding both (i) the transactions that qualify for reporting; and (ii) the category of persons required to report on rejected transactions. Specifically:

    • The Interim Final Rule requires reporting of all “rejected transactions,” which are defined broadly to include any transaction rejected because it would violate sanctions, including transactions “related to wire transfers, trade finance, securities, checks, foreign exchange, and goods or services.”[2]
    • The Interim Final Rule requires reporting by all U.S. persons and persons subject to United States jurisdiction.[3] Previously, only “financial institutions” (“FIs”) were subject to that requirement.
    • In FAQ Number 36, OFAC has advised that transactions should be rejected where the underlying transaction may be prohibited, but there is no blockable interest in the transaction.[4] There is a lack of clarity in how this concept applies to the broader category of persons required to file rejected transaction reports under the Interim Final Rule. OFAC has indicated that it welcomes questions about whether a transaction should be blocked or rejected. We understand that OFAC has received questions seeking clarity on the impact of this rule, in particular, for non-FIs with respect to rejected transactions, and that, as a result, it is considering more precisely what kinds of rejected transactions need to be reported by non-FIs.
    • These changes have potentially significant implications, and each company affected by this Interim Final Rule should review their sanctions compliance-related internal controls and practices to ensure that they are appropriately meeting the new and amended requirements.

    Other Changes to the RPPR

    In addition to expanding the scope of the reporting requirements, the Interim Final Rule expands the scope of the information required to be reported on initial and annual reports of blocked property, as well as in reports on rejected transactions, adding a list of new information to be included on each report.

    OFAC also added a new requirement that goes into effect in 2020 for those U.S. persons who maintain blocked funds in omnibus accounts[5] and submit annual reports. The new regulation requires that annual reports contain a disaggregated list showing each blocked asset contained within an omnibus account.[6]

    Further, OFAC has revised the regulations to allow for the submission of initial and annual reports of blocked property and reports of rejected transactions by “email, U.S. mail, or any other official reporting option, including electronic, as specified by OFAC on its website” and expressed a strong preference to receiving reports by email or electronically.

    The Interim Final Rule also amends 31 CFR § 501.801 to require that applications for specific licenses to engage in transactions otherwise prohibited under 31 C.F.R. Chapter V, or sanctions programs administered by OFAC, be filed through OFAC’s Reporting and License Application Forms page or by mail.[7]

    The Interim Final Rule further clarifies that reports of blocked, unblocked and rejected transactions are subject to release under the Freedom of Information Act (“FOIA”) upon receipt of a valid FOIA request, unless they are exempt from disclosure pursuant to an applicable FOIA exemption.

    The Interim Final Rule expands OFAC’s subpoena power to clarify that OFAC can request “electronic documents,” such as videos or sound recordings, in addition to obtaining the testimony of witnesses and the production of any books, contracts, letters, papers and other hard copy documents relating to any matter under investigation.[8]

    OFAC also revised 31 CFR § 501.701 to accurately describe the penalties imposed for willful violations of the Trading with the Enemy Act (“TWEA”) to reflect the increases to the maximum term of imprisonment from 10 to 20 years under TWEA, as imposed under Section 107(a)(4) of the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010.[9]

    Enforcement Actions

    Subsequent to the issuance of the Interim Final Rule, on Aug. 8, 2019, OFAC issued Findings of Violations to Southern Cross Aviation LLC (“Southern Cross”) and DNI Express Shipping Company (“DNI”) in cases involving alleged failures to properly respond to OFAC administrative subpoenas issued under the RPPR. As reflected below, these actions signal an aggressive approach by OFAC with respect to non-compliance with the RPPR.

    Southern Cross

    The Finding of Violation was issued due to Southern Cross’s failure to provide complete information in response to an administrative subpoena.[10] The subpoena was issued for information regarding transactions and other dealings with Iran, in particular related to a potential sale of helicopters to Iran via an Iranian businessman based in Ecuador. In response to this subpoena, Southern Cross first denied knowing or conducting business with the Iranian businessman or otherwise dealing with Iran, then subsequently admitted that a Southern Cross representative in Ecuador sent technical details to an Ecuadorian group for the potential sale and produced no documentation other than a company manual relating to export management. OFAC then issued a second Administrative Subpoena, specifically requesting documents related to the potential sale; Southern Cross produced a number of documents, including email exchanges directly with the Iranian businessman, as well as other documents related to the potential sale. In determining to issue a Finding of Violation, OFAC considered Southern Cross’s reckless disregard for its obligations under the RPPR by failing to provide accurate and complete information, its actual knowledge of the conduct and its failure to fully cooperate as aggravating factors. OFAC considered the facts that Southern Cross apparently did not complete the sale, as well as their small size and lack of prior sanctions history as mitigating factors.

    DNI

    OFAC issued a Finding of Violation to DNI for violations of the RPPR based on information that DNI provided through outside counsel to OFAC during an investigation.[11] More specifically, OFAC determined, after reviewing DNI’s responses to an administrative subpoena, that the company’s responses contained contradictory, false, materially inaccurate, materially incomplete and misleading information. This was the case even though OFAC reminded DNI of its obligations pursuant to the RPPR after its initial response to the administrative subpoena. In determining to issue a Finding of Violation, OFAC considered DNI’s reckless disregard for sanctions requirements by failing to provide accurate and complete information, its shipment and attempted shipment of goods to Sudan, its failure to correct its responses despite being given an opportunity to do so by OFAC, and its failure to fully cooperate with OFAC’s investigation to be aggravating factors. OFAC viewed the fact that DNI is a small business, has no sanctions history and responded through outside counsel as mitigating factors.

    Read together, these recent enforcement actions relating to the RPPR and the new amendments to the RPPR highlight OFAC’s insistence on receiving comprehensive and truthful information from individuals and companies subject to OFAC regulations.

    Authored by Betty Santangelo, Gary Stein, Melissa G.R. Goldstein, Hannah M. Thibideau and Jennifer M. Opheim.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] 31 C.F.R.§ 501, “Reporting, Procedures and Penalties Regulations,” (June 21, 2019) available here.

    [2] 31 C.F.R. § 501.604-4.

    [3] 31 C.F.R. § 501.604-4.

    [4] “Blocking and Rejecting Transactions,” OFAC Frequently Asked Questions (“FAQ”) no. 36, available here.

    [5] Omnibus accounts are not defined in the regulation.

    [6] 31 C.F.R. § 501.603.

    [7] 31 C.F.R. § 501.801.

    [8] 31 C.F.R. § 501.602.

    [9] 31 C.F.R. § 501.701.

    [10] U.S. Department of the Treasury, Press Release, “Enforcement Information for August 8, 2019,” (Southern Cross) available here.

    [11] U.S. Department of the Treasury, Press Release, “Enforcement Information for August 8, 2019,” (DNI) available here.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2019 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    More insights

  • CMS Finalizes Hospital Price Transparency Requirements, Disclosure of Negotiated Rates

    CMS Finalizes Hospital Price Transparency Requirements, Disclosure of Negotiated Rates

    ARTICLE / CLIENT ALERT

    CMS Finalizes Hospital Price Transparency Requirements, Disclosure of Negotiated Rates

    November 19, 2019

    Read time: 19 min

    Key takeaways
    Overview

    On November 15, the Trump Administration released a final rule requiring hospitals to publicly disclose hospital charges, including negotiated prices with third-party payers by January 1, 2021. We outline key considerations for hospitals and other stakeholders in connection with the rule and its requirements, as well as a chart detailing the specific requirements.

    In depth

    The Trump Administration on November 15, 2019, released a final rule (the Final Rule) requiring hospitals to publicly disclose hospital charges, including negotiated prices with third-party payers by January 1, 2021. More specifically, the Centers for Medicare and Medicaid Services (CMS) is adding a set of new regulations that establish requirements for hospitals to publicly disclose their charges, penalties for non-compliance and details on the specific methods and elements for disclosure.

    CMS originally proposed these requirements in the Calendar Year 2020 Medicare Hospital Outpatient Prospective Payment System Proposed Rule (the Proposed Rule), which we discussed in a prior On the Subject titled “Proposed OPPS Changes for 2020: A review of Four Key Proposals.” Despite significant opposition to the Proposed Rule from the hospital stakeholder community, the Final Rule is materially similar to the Proposed Rule, with only minimal changes. Other than the one-year delay in implementation, the primary difference between the Proposed Rule and Final Rule is the option for hospitals to comply with the disclosure requirements through development of an internet-based “price estimator tool” to allow consumers real-time access to price estimates of identified hospital services.

    One other notable development is that the Administration simultaneously posted a proposed rule that would apply similar requirements on employer-based group health plans and health insurance issuers whereby such entities would be required to disclose price and cost-sharing information to participants, beneficiaries and enrollees up-front. This additional proposed rule is intended to be responsive to a key hospital argument that payers are better positioned to provide actionable price comparison information to consumers, because actual patient liability is driven more by plan- and patient-specific liabilities than hospital negotiated charges.

    It estimated that there are approximately 6,002 hospitals operating within the United States that would become subject to the new disclosure requirements.

    This article outlines key considerations for hospitals and other stakeholders in connection with the Final Rule and its requirements, as well as a chart detailing the specific requirements as set forth in the Proposed Rule and as finalized in the Final Rule.

    I. CRITICAL CONSIDERATIONS

    1. Operational Compliance

    Compliance with the Final Rule will require many hospitals and hospital systems to devote extensive resources to determine particular hospitals’ “standard charges,” which include not only the hospital’s chargemaster, but also payer-specific charges, discounted cash prices (to the extent such prices exist), minimum negotiated charges and the maximum negotiated charges, not only for individual items and services, but also for service packages in cases where standard charges exist. Moreover, hospitals will be required to identify the relevant universe of 300 “shoppable” services at each hospital based on billing data, as well as the ancillary services that the hospital “customarily” provides with the shoppable services.

    These tasks can be expected to consume significant resources from hospitals as they:

    • review third-party payer contracts to identify negotiated rates,
    • determine whether the hospital offers any “discounted cash prices,”
    • review utilization data and the nature of particular services to determine a universe of 300 “shoppable” services,
    • assess the ancillary services that are “customarily” provided with these “shoppable” services, and then
    • prepare and publish this data in a compliant format.

    Operational compliance with the Final Rule can be expected to involve a number of nuanced analyses and determinations across an array of individuals across hospital departments.

    The Final Rule’s “internet-based price estimator tool” option for hospitals may relieve some of the Final Rule’s burden for hospitals that have already established qualifying tools, or to the extent developing such a tool would be less burdensome than otherwise meeting the requirements of making public the hospital’s standard charges for selected shoppable services in a consumer-friendly manner. However, even hospitals that offer a qualifying internet-based price estimator tool will be required to make public all standard charges for all hospital items and services online.

    Finally, hospitals expecting to incur significant costs to come into, and maintain, compliance with the Final Rule’s requirements may consider those costs in the context of the size of the Civil Monetary Penalties for noncompliance, which is capped at $300 per day and would total $109,500 in penalties over the course of the year. In the Final Rule, CMS acknowledged comments expressing concern that some hospitals may prefer to forgo meeting the Final Rule’s disclosure requirements, and instead face compliance actions including a $300 maximum daily penalty. Hospitals considering such an option would want to consider the possibility of CMS increasing the penalty in future rulemaking (a possibility CMS expressly contemplated in the Final Rule), potential reputational implications of noncompliance, and market dynamics if certain hospitals are silent as to published rates while other hospitals have published rates. Intentional noncompliance with federal law may also have implications in a variety of other contexts, such as accreditation and certifications of compliance in various settings and transactional representations and warranties regarding compliance with federal law, among others

    2. Market Dynamics

    Although the potential market dynamics of the Final Rule and public accessibility to pricing information are not expected to materialize until after hospitals have come into compliance with the Final Rule and patients begin reviewing the data to a meaningful extent, hospitals may benefit by beginning to anticipate these market dynamics well before standard charges are published. Anticipating the effects of the pricing information on the market for hospital services, however, is likely a task for consultants and economists, rather than individual hospitals or systems.

    As CMS acknowledged in the Proposed and Final Rules, any market effects are largely unknown at this time and will likely vary based on a variety of local and regional factors, such as the proximity of hospitals providing similar services, patients’ beliefs regarding the quality of care provided at various hospitals within a reasonable proximity, and the disparity of disclosed standard charges at various hospitals and in particular specialties. Whereas rural hospitals that are relatively distant from other hospitals with similar reputations and charges may experience little market impact from the Final Rule’s disclosure requirements, urban hospitals in close proximity to substitute competitors with different reputations and charges may experience greater market impact. Hospitals anticipating a potential adverse effect may consider strategies to shift the potential trajectory

    3. Intra-Health System Dynamics

    Because the Final Rule will require separately licensed hospitals within a single health system to comply with the reporting requirements, differing standard charges at particular hospitals may result in intra-health system dynamics, such that patients may prefer to receive services at one system hospital as opposed to another based on the difference in standard charges between the hospitals. Similarly, because the Final Rule will require hospitals to include ancillary services among the “shoppable” services with disclosed standard charges, differences in the ancillary services customarily provided with shoppable services furnished at one hospital as opposed to another hospital in a health system may similar result in patient preferences to be seen at one system hospital or another. Similarly, because standard charges will distinguish between inpatient and outpatient procedures, patients may be more inclined to have procedures furnished in lower-charge settings (e.g., outpatient settings) as opposed to typically higher-charge settings (e.g., inpatient settings)

    Larger health systems preparing for disclosure of standard charges should consider how differing standard charges and customarily furnished ancillary services at various hospitals may impact patient perceptions and preferences, and consider pricing or operational strategies that may shape the potential impact of the Final Rule on the health system’s internal dynamics.

    4. Third-Party Payer Relationship

    Widespread hospital disclosure of standard negotiated charges with third-party payers can be expected to dramatically shape many hospitals’ negotiations and relationships with third-party payers. Rate comparisons among hospitals are likely to become a key negotiating feature between hospitals and third-party payers, where many hospitals with lower rates than proximate, similarly situated hospitals may feel that their rates are sub-market and negotiate with third-party payers for rate increases. At the same time, hospitals with higher rates than proximate, similarly situated hospitals may be foresee certain patients selecting competitor hospitals due to their comparatively lower negotiated rates and be inclined to reduce their own negotiated rates.

    The Final Rule’s effect on third-party payer relationships is likely to be defined by the facts and circumstances of particular localities and regions, including the number of proximate hospitals and their respective reputations, services, patient populations and other factors.

    5. Patient Demographics and Procedure Utilization

    To the extent the Final Rule’s transparency requirements may influence patient choice among hospitals, differentials in standard charges for categories of procedures from one hospital to another may result in shifting patient demographics and procedure utilization. For example, hospitals with lower charges for certain types of services may attract patients with diagnoses that typically receive those types of services. Utilization of procedures with relatively high standard charges across all reasonably proximate hospitals may decrease as patients may forgo certain relatively high-charge procedures, particularly in cases where another, lower-charge procedure may be available.

    6. Litigation

    Finally, hospitals should consider the potential impact that anticipated litigation may have on the Final Rule and its various requirements. The rule claims that CMS has authority based on a provision in the Public Health Services Act requiring each “hospital” operating within the United States to each year establish, update and make public a list of the hospital’s “standard charges” for “items and services” provided by the hospital. Following publication of the Proposed Rule, a number of hospitals publicly indicated an intent to sue CMS to block implementation of the requirements if finalized as proposed. The opposition to the requirements and possible legal theories that might be used in litigation were reflected in the comments to the Proposed Rule. Commenters explained that negotiated rates are proprietary, and requiring their disclosure would infringe upon intellectual property rights recognized by Congress through the Defend Trade Secrets Act of 2016. Other commenters indicated that disclosure of payer-specific negotiated charges was limited under the Freedom of Information Act (FOIA), which protects trade secrets and confidential commercial or financial information against broad public disclosure. Other comments asserted that the requirement to disclose payer-specific negotiated charges would violate the First Amendment by compelling speech. Other commenters still noted that some third-party payer contracts prohibit disclosure of the negotiated rates.

    In the Final Rule, CMS clearly contemplates litigation (e.g., in CMS’s discussion of de-identified minimum negotiated charges, it noted that it intends all five definitions of “standard charges” to be “severable,” such that if a court were to invalidate the inclusion of an individual definition, the remaining definitions would remain defined as types of standard charges) and acknowledges each of these legal challenges, but recognizes it continues to believe it has the authority to promulgate the requirements. On the day the Final Rule was released, the American Hospital Association, Association of American Medical Colleges, Children’s Hospital Association and Federal of American Hospitals issued a statement indicating they would soon join with member hospitals to file a legal challenge to the rule on grounds including that it exceeds the Administration’s authority. The January 1, 2021, effective date may delay litigation until that time, as courts often dismiss litigation as not ripe in advance of implementation.

    II. OVERVIEW OF THE FINAL RULE

    Overview of the Final Rule

     

    Proposed Rule

    Final Rule

    Applicability: Hospitals and Locations

    Defined “hospital” subject to the disclosure requirement as an institution licensed as a hospital pursuant to a state’s hospital licensing law, or which is approved by the state as meeting the standards established for such licensing.

    This definition would apply to hospitals regardless of their Medicare enrollment status or designation, and it would include critical access hospitals (CAHs), inpatient psychiatric facilities, sole community hospitals and inpatient rehabilitation facilities, but not ambulatory surgical centers.

    In cases where a hospital had different locations operating under a consolidated or single state license and different hospital locations offered different services with different associated standard charges, the Proposed Rule’s requirements would separately apply to each hospital location such that each hospital location would be required to make public a separate identifiable list of its standard charges.

    Finalized without modification.

     

    Items and Services

    “Items and services” defined as all items and services, including individual items and services and “service packages,” that could be provided by a hospital to a patient in connection with an inpatient admission or outpatient department visit for which the hospital had established a standard charge.

    Items and services would also include services furnished by physicians and non-physician practitioners who were employed by the hospital, but not practitioners who were not employed by the hospital but provided services at a hospital location.

    “Service packages” would mean an aggregation of individual items and services into a single service with a single charge.

    “Items and services” and “Service packages” finalized without modification, but the Final Rule also finalized a technical change to include examples of “items and services” in the regulation, including:

    • supplies and procedures;
    • room and board;
    • use of the facility and other items;
    • services of employed physicians and non-physician practitioners; and
    • any other items or services for which a hospital has established a “standard charge.”

    Standard Charges

    “Standard charges” defined as including two sets of charges:

    (1) “gross charges”
    (2) “payer-specific negotiated rates.”

    The Final Rule adopted the proposed definition of “standard charges” as including gross charges and “payer-specific negotiated rates,” but it also added three additional types of “standard charges” that must be disclosed:
    (1) discounted cash prices
    (2) de-identified minimum negotiated charges
    (3) de-identified maximum negotiated charges.

    Gross Charges

    “Gross charges” were defined as the charge for an individual item or service that is reflected on a hospital’s chargemaster, absent any discounts.

    Finalized without modification.

    Payer-Specific Negotiated Charges

    “Payer-specific negotiated charges” were defined as the charge that the hospital negotiated with a third-party payer for an item or service.

    “Third-party payer” would include an entity that is, by statute, contract or agreement, legally responsible for payment of a claim for a healthcare item or service (including Medicare Advantage plans).

    Finalized without modification.

    Discounted Cash Price

    The Proposed Rule considered defining a type of “standard charge” as the “discounted cash price,” defined as the price the hospital would charge individuals who pay cash (or cash equivalent) for an individual item or service or service package.

    The Final Rule finalized the definition of “discounted cash price” to mean the charge that applies to an individual who pays cash (or cash equivalent) for a hospital item or service.

    The Final Rule clarified that the “discounted cash price” would reflect the discounted rate published by the hospital, unrelated to any charity care or bill forgiveness that a hospital may choose or be required to apply to a particular individual’s bill.

    De-Identified Minimum and Maximum Negotiated Charges

    CMS considered in the Proposed Rule defining as types of “standard charge” the minimum and maximum negotiated charges of the distribution of all negotiated charges across all third-party payer plans and products.

    The Final Rule finalized “de-identified minimum negotiated charge” to mean the lowest charge that a hospital has negotiated with all third-party payers for an item or service, and “de-identified maximum negotiated charge” to mean the highest charge that a hospital has negotiated with all third-party payers for an item or service.

    Requirements for Disclosure

     

     

    Standardized Elements

    Hospitals would be required to disclose the following elements:

    • Description of each item or service
    • Gross charge for each individual item or service when provided in, as applicable, inpatient and outpatient settings
    • Payer-specific negotiated charge when provided in, as applicable, inpatient and outpatient settings
    • Code used by the hospital for accounting or billing for the item or service (e.g., CPT code, HCPCS code, DRG, NDC);
    • Revenue code, as applicable

    The list of items finalized in the Final Rule include the proposed standardized elements and added two additional elements:

    • De-identified minimum and maximum negotiated charges that apply to each item or service when provided in, as applicable, inpatient and outpatient settings
    • Discounted cash price that applies to each item or service when provided in, as applicable, inpatient and outpatient settings

    Location and Accessibility

    Hospitals would have discretion to choose the internet location to post its file containing the list of standard charges so long as the file was displayed on a publicly available web page, was “displayed prominently” and clearly identified the hospital location with which the standard charges information was associated, and the standard charge data was “easily accessible,” “without barriers” and could be digitally searched.

    “Displayed prominently” would mean that the value and purpose of the web page and its content was clearly communicated, that there was no reliance on breadcrumbs to help with navigation, and that the link to the standard charge file was visually distinguished on the web page.

    “Easily accessible” would mean that standard charge data are presented in a single machine-readable file that is searchable and that the standard charges file was posted on a website that could be accessed with the fewest number of clicks.

    “Without barriers” would mean the data could be accessed free of charge, and that users would not have to input information or register to access or use the standard data file.

    Finalized without modification.

    “Shoppable” Services

     

     

    Proposed Definitions

    “Shoppable services” was defined as a “service package” that could be scheduled by a healthcare consumer in advance. These are typically routinely provided in non-urgent situations that do not require immediate action or attention to the patient, thus allowing patients to price shop and schedule a service at a time that is convenient for them.

    Hospitals would need to make public the payer-specific negotiated charge for a shoppable service that is grouped together with charges for associated ancillary services.

    An “ancillary service” would be defined as an item or service a hospital customarily provides as part of or in conjunction with a shoppable primary service, including laboratory, radiology, drugs, delivery room, operating room, therapy services, hospital fees, room and board charges, and charges for employed professional services.

    “Ancillary services” may also include other special items or services for which charges are customarily made in addition to a routine service charge. To the extent a hospital customarily provides (and bills for) such services as part of or in conjunction with the primary service, the hospital would need to group the service charge along with the other payer-specific negotiated charges that were displayed for the shoppable service.

    The Final Rule finalized the definition of “shoppable services” and related definitions as proposed, with the exception that it modified its definition of “shoppable services” to remove reference to a “service package,” because not every shoppable service will be a “service package.”

    CMS emphasized that it was still finalizing its requirement that hospitals display ancillary services along with each primary shoppable service, as applicable.

    Selected Shoppable Services

    Hospitals required to make public a list of their payer-specific negotiated charges for as many of the 70 shoppable services CMS identified in the Proposed Rule that are provided by the hospital, and hospitals would be allowed to select as many additional shoppable services as necessary for the combined total of at least 300 shoppable services.

    CMS proposed that hospitals select such services based on the utilization or billing rate of the services in the past year.

    The Final Rule generally finalized the rule as proposed, but created an exception for some small or specialty hospitals that do not offer 300 services that could be scheduled by consumers in advance, who must display as many of the services it provides that could be scheduled by patients in advance.

     

    Data Elements

    Hospital would be required to make available online to the public online the following elements:

    • Plain language description of each shoppable service
    • Payer-specific negotiated charge applicable to the shoppable service
    • A list of all of the associated ancillary items and services the hospital provides with the shoppable service, including the payer-specific negotiated rate for each ancillary item or service
    • The location at which each shoppable service is provided in the hospital
    • Any primary code used by the hospital for accounting or billing for the shoppable service (e.g., CPT, HCPCS, DRG)

    The Final Rule makes a variety of modifications to the list of data elements necessary to be disclosed, to include:

    • Plain language description of each shoppable service
    • Payer-specific negotiated charge, discounted cash price, de-identified minimum and maximum negotiated charge applicable to the shoppable service (and corresponding ancillary services, as applicable)
    • The location at which each shoppable service is provided in the hospital, including whether the shoppable service applies to the inpatient setting, outpatient setting or both (and if the standard charge for the shoppable service varies based on location or whether the hospital provides the shoppable service in the inpatient versus the outpatient setting, the hospital would be required to identify each set of standard charges
    • Any primary code used by the hospital for accounting or billing for the shoppable service (e.g., CPT, HCPCS, DRG)

    Display, Location and Accessibility

    Hospitals would retain flexibility on how best to display the payer-specific negotiated charge data and proposed associated data elements to the public online, so long as the website is easily accessible to the public.

    The data must be “displayed prominently,” clearly identify the hospital location with which the standard charge information is associated, the standard charge data must be “easily accessible” and “without barriers,” and the data must be easily searched. Definitions of these terms are provided above.

    Finalized without material modifications.

    Internet-Based Price Estimator Tool

    Silent

    The Final Rule created a new option for hospitals to meet the otherwise applicable requirements for displaying shoppable services in a consumer-friendly manner if the tool:

    • Provides estimates for as many of the 70 CMS-specified shoppable services that are provided by the hospital, and as many additional hospital-selected shoppable services as is necessary for a combined total of at least 300 shoppable services
    • Allows healthcare consumers to, at time they use the tool, obtain an estimate of the amount they will be obligated to pay the hospital for the shoppable service
    • Is prominently displayed on the hospital’s website and accessible to the public without charge and without having to register or establish a user account or password

    Monitoring, Enforcement and Appeals

    CMS would monitor compliance predominantly based on complaints made by individuals and entities.

    The Proposed Rule suggested a daily Civil Monetary Penalty of $300 per day for hospital noncompliance with the disclosure requirements.

    Finalized as proposed, with the addition that CMS may itself audit hospitals’ websites to determine compliance.

     

    Authors

    Eric Zimmerman

    Partner

    Washington, DC

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    More insights

  • How Any Website Could Be Considered a Joint Controller

    ARTICLE

    How Any Website Could Be Considered a Joint Controller

    November 18, 2019

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Owners of Enjoined Company Personally Liable for Monkeying around with Injunction

    ARTICLE

    Owners of Enjoined Company Personally Liable for Monkeying around with Injunction

    November 15, 2019

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights